Accuray researchers investigated the potential for adapting the CyberKnife® System's unique Synchrony® Respiratory Tracking System to an experimental TomoTherapy System. The study showed Synchrony-like real-time respiratory motion management is technically feasible using TomoTherapy technology, enabling a high level of accuracy when delivering dose to tumors that move with respiration.
The dosimetric impact of using real-time primary jaw/multileaf collimator (MLC) compensation approaches to mitigate motion during TomoHelical™ delivery was analyzed by a team of researchers from the University of Wisconsin, Madison and Accuray. Dose was calculated for treatment plans assuming 1) no motion, 2) respiratory motion, and 3) respiratory motion compensated by adjusting the jaw and MLC position during delivery. The team found that a jaw and MLC compensation approach mitigated the large difference between planned and delivered dose caused by motion, thus enabling reductions in margin.
"The data presented at this year's AAPM speak to the precision, accuracy and effectiveness of Accuray's entire portfolio of radiation therapy systems," said Calvin Maurer, Ph.D., Vice President and Chief Technology Officer at Accuray. "The Radixact™ System findings reinforce what customers are experiencing in their day-to-day practice and demonstrate its value to the radiation oncology team and their patients. In partnership with our customers we are continuing to develop clinically relevant technological advances such as the Radixact System, PreciseART™ Adaptive Solution and PreciseRTX™ Retreatment Option, which make it easier for clinicians to provide patients with the best possible treatment for them at each stage of their cancer treatment journey."

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, future developments of our technologies and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.

Rad Oncology Homepage